immatics Presents Positive Phase II Results With its Therapeutic Cancer Vaccine IMA910 in Patients With Advanced Colorectal Cancer at the 2012 ASCO Gastrointestinal Cancers Symposium
TUEBINGEN, Germany, January 24, 2012 /PRNewswire/ –
Study shows a consistent association between immune response to IMA910 and all
clinical endpoints and an excellent tolerability profile
immatics’ unique XPRESIDENT(TM) platform delivers a second promising therapeutic
cancer vaccine candidate
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing
advanced therapeutic vaccines that are active against cancer, announced positive results
from its Phase II clinical trial with IMA910 in patients with advanced colorectal cell
carcinoma (CRC) which were presented at the Gastrointestinal Cancers Symposium of the 2012
American Society of Clinical Oncology (ASCO) in San Francisco. IMA910 comprises 13
tumor-associated peptides (TUMAPs) identified directly from patients suffering from
The IMA910 study recruited 92 patients with advanced/metastatic CRC who had shown no
progression following 12 weeks of first line oxaliplatin-based chemotherapy and who had
decided to take a so called ‘drug holiday’ from their chemotherapy regimen. Patients
received one single infusion of cyclophosphamide (CY) as immunomodulator prior to the
first vaccination with the multi-peptide vaccine IMA910. They were treated with IMA910
plus GM-CSF and with or without an additional immunomodulator imiquimod. All patients
received up to 16 vaccinations with IMA910 over a period of 9 months. The trial was
conducted at 51 centers in 9 European countries.
The study measured overall survival, disease control rate, T-cell responses to IMA910,
the effect of imiquimod on immune response, the association of immune response with
clinical benefit, and safety and tolerability.
The data from the study confirmed that IMA910 is able to stimulate relevant immune
responses against the tumor-associated peptides (TUMAPS) in IMA910 in the majority of
patients vaccinated. Intriguingly, when looking at the clinical outcome of patients who
had detectable T cell responses against two or more of the tumor-derived peptides (TUMAPs)
contained in IMA910, a consistently better clinical outcome (disease control,
progression-free survival and overall survival) was observed compared to those who did not
have a detectable multi-T-cell response. Moreover patients who mounted both CD8+ and CD4+
multi-T-cell responses did not reach the median survival after more than 28 months of
follow-up compared to a 16 months median survival time in those who did not (HR 0.53;
In addition, the data presented show that IMA910 is very well tolerated with
injection-site reactions being the most frequent side effect seen.
Carsten Reinhardt, Chief Medical Officer of immatics said: “The Phase II trial results
with IMA910 in this challenging setting in patients with advanced colorectal carcinoma are
very encouraging. The data that we have generated show a clear association between the
patient’s ability to mount an immune response to the tumor associated peptides (TUMAPS) in
IMA910 and overall survival. Since the baseline characteristics of immune responders and
non-responders were very similar in terms of risk factors, this strongly suggests a true
clinical activity of this novel vaccine.”
Paul Higham, CEO of immatics said: “The fact that we have now generated positive Phase
II results with our two lead therapeutic vaccines, IMA901 for renal cell carcinoma and
IMA910 for colorectal cancer highlights the power of our TUMAP based approach and the
ability of our XPRESIDENT(TM) platform to generate further exciting treatment options for
a broad range of cancers.”
The poster presented at the Gastrointestinal Cancers Symposium of the American Society
of Clinical Oncology (ASCO) in San Francisco contains a more detailed analysis of the
survival, safety and immune response data generated with IMA910 in this Phase II study.
The poster can be downloaded at http://www.immatics.com.
IMA910 is therapeutic cancer vaccine comprising 13 tumor-associated peptides (TUMAPs)
that are frequently found to be over-expressed in the majority of patients suffering from
colorectal cancer. These TUMAPs were identified based on the analysis of primary tumor
tissue and have been chosen due to their ability to activate cytotoxic T cells and T
helper cells against colorectal cancer. As with all immatics’ vaccines, IMA910 has been
designed to elicit a strong, clinically relevant immune response to a specific tumor type.
The TUMAPs were selected from in over 2,000 peptides identified via immatics’ unique
immatics biotechnologies is a clinical-stage biopharmaceutical company developing
advanced therapeutic vaccines that are active against cancer. immatics’ lead product,
IMA901, is in a pivotal Phase III study after completing a successful Phase II trial in
renal cell carcinoma. immatics’ pipeline also includes IMA910, in Phase II for colorectal
cancer, and IMA950, which is being developed for glioma in Phase I studies.
immatics’ technology platform rapidly generates defined therapeutic cancer vaccines
which are based on multiple tumor-associated peptides (TUMAPs) with the ability to
specifically stimulate the immune system against cancer cells. These vaccines – comprising
multiple peptides confirmed to be naturally presented by real tumor tissue – offer the
prospect of greater effectiveness than existing therapeutic approaches combined with fewer
side effects. immatics’ products are ‘drug like’ with stable, off-the-shelf formulations
and robust easily scalable manufacturing.
immatics is based in Tuebingen and Munich, Germany, and has raised EUR108 million
(US$140 million) in private equity in three financing rounds to date, with the last EUR54
million completed in September 2010.
For additional information on immatics please visit http://www.immatics.com or contact: Paul Higham, CEO Katrin Eckert, Assistant to the Management immatics biotechnologies GmbH Phone: +49-7071-5397-110 E-mail: firstname.lastname@example.org Citigate Dewe Rogerson David Dible / Chris Gardner / Sita Shah Phone: +44-207-638-9571 E-mail: email@example.com
SOURCE immatics biotechnologies GmbH